After about two years of treatment with the experimental therapies tobevibart and elebsiran, nearly…
Articles by Marisa Wexler, MS
Researchers have identified three proteins that may be key targets for treating primary sclerosing cholangitis (PSC), and one of…
A global clinical trial testing Mirum Pharmaceuticals‘ maralixibat for treatment-resistant itching, or pruritus, associated with rare cholestatic conditions…
AX-0810, an experimental treatment for biliary atresia and primary sclerosing cholangitis (PSC), has so far been well tolerated…
Bepirovirsen added to standard-of-care medications led to higher functional cure rates for people with chronic hepatitis B than standard…
Madrigal Pharmaceuticals, the maker of Rezdiffra (resmetiron), has acquired three new experimental treatments for metabolic dysfunction-associated steatohepatitis (MASH), a…
Health Canada has expanded its approval of Abbvie’s oral therapy Maviret (glecaprevir/pibrentasvir), making it the first eight-week, pan-genotypic treatment…
About one year of treatment with Altimmune’s experimental therapy pemvidutide led to reductions in noninvasive markers of liver scarring…
Throughout 2025, the team at Liver Disease News has reported on the latest research and advances in care related to…
Researchers in the U.S. have developed a rapid point-of-care test that detects active hepatitis C infection by identifying HCV…